Which of the following antimicrobials is effective against an organism producing extended-spectrum beta-lactamases?

Explanation

## Correct Answer: D. Piperacillin – tazobactam Extended-spectrum beta-lactamases (ESBLs) are plasmid-mediated enzymes produced by Gram-negative bacteria (especially *Klebsiella pneumoniae*, *E. coli*, *Proteus*, *Enterobacter*) that hydrolyze third-generation cephalosporins and penicillins. The discriminating principle is that **beta-lactamase inhibitors must be present to overcome ESBL resistance**. Piperacillin–tazobactam is a combination of an extended-spectrum penicillin (piperacillin) with a beta-lactamase inhibitor (tazobactam). Tazobactam irreversibly binds to and inactivates ESBL enzymes, protecting piperacillin from hydrolysis and restoring its bactericidal activity against ESBL-producing organisms. This combination is the preferred empirical choice in Indian hospitals for suspected ESBL infections (per ICMR and IAP guidelines). The beta-lactamase inhibitor is essential—piperacillin alone would be hydrolyzed. Amoxicillin–clavulanic acid, while containing clavulanic acid (a beta-lactamase inhibitor), has limited activity against many ESBL-producing Gram-negatives because amoxicillin itself has poor Gram-negative coverage and clavulanic acid is less potent against ESBLs than tazobactam. Piperacillin–tazobactam remains the gold standard for ESBL coverage in serious infections in Indian clinical practice. ## Why the other options are wrong **A. Penicillin** — Penicillin is rapidly hydrolyzed by beta-lactamases (including ESBLs) and has no beta-lactamase inhibitor component. It is completely ineffective against ESBL-producing organisms. This is the most obviously wrong option—penicillin predates ESBL resistance by decades and offers no protection. **B. Ceftriaxone** — Ceftriaxone is a third-generation cephalosporin and is a *substrate* for ESBL enzymes—ESBLs were originally defined by their ability to hydrolyze ceftriaxone. Although it has a beta-lactam ring, it lacks a beta-lactamase inhibitor. Ceftriaxone monotherapy is contraindicated in confirmed ESBL infections. This is a classic NBE trap pairing ESBL with a cephalosporin. **C. Amoxicillin – clavulanic acid** — While amoxicillin–clavulanic acid contains clavulanic acid (a beta-lactamase inhibitor), it has limited efficacy against ESBL-producing Gram-negatives. Clavulanic acid is a weaker inhibitor of ESBLs compared to tazobactam, and amoxicillin itself has poor Gram-negative penetration. It is not recommended for serious ESBL infections in Indian guidelines. Oral formulations are sometimes used for mild UTIs, but IV piperacillin–tazobactam is superior for systemic ESBL disease. ## High-Yield Facts - **ESBL-producing organisms** are resistant to third-generation cephalosporins (ceftriaxone, cefotaxime) and penicillins; resistance is conferred by plasmid-mediated beta-lactamase. - **Piperacillin–tazobactam** is the preferred empirical agent for suspected ESBL infections in India; tazobactam irreversibly inhibits ESBL enzymes. - **Ceftriaxone monotherapy fails** in ESBL infections because ESBLs were originally defined by their ability to hydrolyze third-generation cephalosporins. - **Amoxicillin–clavulanic acid** has limited ESBL coverage; clavulanic acid is a weaker ESBL inhibitor than tazobactam, and amoxicillin has poor Gram-negative activity. - **Carbapenem-resistant Enterobacteriaceae (CRE)** are emerging in Indian hospitals; piperacillin–tazobactam remains effective against most ESBL strains but not CRE. - **ICMR/IAP guidelines** recommend piperacillin–tazobactam or carbapenems (meropenem, ertapenem) for serious ESBL infections in hospitalized Indian patients. ## Mnemonics **ESBL Killers** **P**iperacillin–tazobactam, **C**arbapenems (meropenem, ertapenem), **F**luoroquinolones (for mild infections). Remember: **PCF** = Piperacillin–tazobactam is first-line for serious ESBL. **Why Cephalosporins Fail in ESBL** **E**SBLs = **E**xtended-spectrum, meaning they *extend* their hydrolytic activity to **3rd-gen cephalosporins**. Ceftriaxone is the *definition* of what ESBLs attack. ## NBE Trap NBE pairs ESBL with ceftriaxone (option B) to trap students who know cephalosporins are broad-spectrum but forget that ESBLs were *defined* by their ability to hydrolyze third-generation cephalosporins. The trap exploits incomplete understanding of ESBL mechanism. ## Clinical Pearl In Indian tertiary-care hospitals, ESBL-producing *K. pneumoniae* and *E. coli* are now endemic in ICUs and wards. A septic patient with a positive blood culture from a urinary source should receive empirical piperacillin–tazobactam (or carbapenem) pending culture and susceptibility results—delaying appropriate coverage increases mortality in sepsis. _Reference: KD Tripathi Pharmacology Ch. 46 (Beta-lactams and Beta-lactamase Inhibitors); Jawetz Microbiology Ch. 10 (Gram-negative Rods); ICMR Guidelines on Antimicrobial Stewardship_